Glucose metabolism and Alzheimer's disease.

Cellular Neurobiology Laboratory, The Salk Institute for Biological Studies, 10010 N, Torrey Pines Road, La Jolla, CA 92037, USA.
Ageing Research Reviews (Impact Factor: 7.63). 06/2005; 4(2):240-57. DOI: 10.1016/j.arr.2005.02.003
Source: PubMed

ABSTRACT The brain is the organ with the highest basal rate of glucose consumption. Most of the energy generated by the oxidation of glucose is used for the work necessary to maintain the ionic balances associated with synaptic transmission. When the nervous system is subjected to the oxidative stress of age-associated disease, there is a redistribution of glucose breakdown to pathways that more efficiently produce molecules involved in antioxidant metabolism. This shift is at least in part mediated by the transcription factor HIF-1. The clinical implications of this change in glucose metabolism are discussed in the context of aging and Alzheimer's disease.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Decreased brain energy metabolism is correlated with cognitive impairment in Alzheimer’s disease (AD). Accumulating evidence indicates that lactate and monocarboxylate transporters (MCTs) participate in brain energy metabolism. To date, changes in lactate level and expression of MCTs in AD remain unclear. This study was conducted to detect the changes in lactate content and expression of MCT2 in Aβ25-35-treated rat model of AD. Sprague–Dawley rats were randomly divided into control and model groups, which received bilateral intrahippocampal injections of saline and Aβ25-35, respectively. Cognitive functions were detected by Morris water-maze test. Lactate content in the cerebral cortex and hippocampus was measured by absorbance assay. The MCT2 level in the brain was examined by immunohistochemistry and Western blot. Morris water-maze test showed that the model group exhibited impaired learning and memory compared with the control group. Lactate content in the cerebral cortex and hippocampus was decreased in the model group compared with that in the control group. Immunohistochemistry and Western blot showed that the expression of MCT2 in the model group significantly decreased compared with that in the control group. Results indicate that decreased lactate content and downregulated MCT2 expression in the cerebral cortex and hippocampus reflected impaired energy metabolism in the brain, which may participate in the pathologic progression of AD.
    Neurological Sciences 02/2015; DOI:10.1007/s10072-015-2087-3 · 1.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Context: Involvement of reactive oxygen species (ROS) in a variety of physiological and pathological processes has attracted a growing interest. In fact, identification of this global signaling system has provided new insights into underlying pathophysiological mechanisms of various diseases such as Alzheimer’s disease (AD). Understanding this information may lead to the development of novel therapeutic strategies. Evidence Acquisitions: Limited efficacy of current medications for neurological disorders and dementias such as AD has led to considerable research interests in new drug development. Based on the modulatory effects of the Fenton reactions with transition metals such as iron, copper, zinc and aluminum on ROS and the effect of free radicals on neuroinflammatory and neurodegenerative processes, we hypothesized that pharmacological manipulation of the transition metals gated hydroxyl ion might be beneficial in treating neurological disorders such as AD. Results: Catalytic activities of transition metals gated by the Fenton reactions are involved in the survival and pathological signaling pathways, neural plasticity, and neuroprotection. Furthermore, ROS and RNS have proved to exhibit overwhelming pathological effects leading to a variety of neurological disorders. Conclusions: In the present investigation, an overview was made on regulatory role of the Fenton reaction gated catalytic activities of transition metals and some evidence regarding their mechanisms leading to Alzheimer’s disease. Based on the neuroinflammatory and neurodegenerative effects of transition metals, drugs with antagonizing effects could be a promising therapeutic alternative for Alzheimer’s disease.
    07/2014; 2(3):1-8. DOI:10.5812/archneurosci.20078
  • [Show abstract] [Hide abstract]
    ABSTRACT: To develop successful therapies that prevent or treat neurodegenerative diseases requires an understanding of the upstream events. Ageing is by far the greatest risk factor for most of these diseases, and to clarify their causes will require an understanding of the process of ageing itself. Starting with the question Why do we age as individual organisms, but the line of pluripotent embryonic stem cells and germ cells carried by individuals and transmitted to descendants is immortal? this review discusses how the process of cellular differentiation leads to the accumulation of biological imperfections with ageing, and how these imperfections may be the cause of chronic inflammatory responses to stress that undermine cellular function. Both differentiation and inflammation involve drastic metabolic changes associated with alterations in mitochondrial dynamics that shift the balance between aerobic glycolysis and oxidative phosphorylation. With ageing, mitochondrial dysfunction can be both the cause and consequence of inflammatory processes and elicit metabolic adaptations that might be either protective or become progressively detrimental. It is argued here that an understanding of the relationship between metabolism, differentiation and inflammation is essential to understanding the pathological mechanisms governing brain health and disease during ageing. Copyright © 2015. Published by Elsevier B.V.
    Ageing Research Reviews 02/2015; DOI:10.1016/j.arr.2015.02.001 · 7.63 Impact Factor